 Home > Active Ingredient News > Antitumor Therapy > JCO: The efficacy of nivolumab combined with ipilimumab in maintenance treatment of advanced small cell lung cancer

JCO: The efficacy of nivolumab combined with ipilimumab in maintenance treatment of advanced small cell lung cancer

 Last Update: 2021-03-30
 Source: Internet
 Author: User

Tags

clinical trial regulation

3 8 1 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Nivolumab is a fully human anti-PD-1 antibody, and Ipilimumab is a fully human anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody.

Immunity In patients with melanoma and renal cell carcinoma, the combined treatment of nivolumab + ipilimumab achieved an overall survival (OS) that exceeded the previous standard treatment.

A previous trial published in the New England Journal of Medicine (NEJM) suggested that patients with non-small cell lung cancer ( NSCLC ) who used nivolumab + ipilimumab had a higher response rate than the nivolumab monotherapy group , Especially in patients whose tumors express PD-L1.

The response rate of patients with non-small cell lung cancer ( NSCLC ) treated with nivolumab + ipilimumab is higher than that in the nivolumab monotherapy group, especially in patients whose tumors express PD-L1.

ASCO

CheckMate 451 is a double-blind phase III trial that evaluates the difference in the efficacy of nivoliyu combined with ipilimumab and nivoliyu monotherapy as a maintenance treatment after first-line chemotherapy for ED-SCLC.

The participants were randomly assigned (1:1:1) to the combination medication group or single-agent treatment group.

The primary endpoint of the study was the overall survival (OS) of the nivoliu combined with ipilimumab group compared with placebo.

Results A total of 834 patients received randomized treatment.

In general, compared with placebo, patients in the nivouliu combined with ipilimumab treatment group did not significantly prolong OS (HR=0.

In patients with tumor mutation burden ≥13 mutations/MB, the OS benefit trend of the nivoliu combined with ipilimumab treatment group was observed.

For patients with ED-SCLC who did not progress with first-line chemotherapy, maintenance therapy with nivoliyu combined with ipilimumab did not prolong OS.

references:

Taofeek K.

org/doi/full/10.
1200/JCO.
20.
02212" target="_blank" rel="noopener">Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.